Monoclonal antibodies in the study and therapy of hematopoietic cancers

[1]  I. Bernstein,et al.  THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA , 1992, Transplantation.

[2]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[3]  A. Kung,et al.  Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. , 1992, Cancer research.

[4]  J. Irvin,et al.  In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia , 1992 .

[5]  D. Arthur,et al.  In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1992, Blood.

[6]  I. Bernstein,et al.  Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. , 1992, Blood.

[7]  I. Bernstein,et al.  Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. , 1992, Cancer research.

[8]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion , 1992 .

[9]  T. Barbui,et al.  Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features , 1992, Cancer.

[10]  F. Uckun,et al.  Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. , 1992, Cancer research.

[11]  I. Bernstein,et al.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. , 1992, Cancer research.

[12]  S. Shah,et al.  Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.

[13]  G. Weiner,et al.  Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. , 1991, Journal of immunology.

[14]  L. Nadler,et al.  An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. , 1991, Cancer research.

[15]  J. Uhr,et al.  Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. , 1991, Cancer research.

[16]  J. Eary,et al.  Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. , 1991, Blood.

[17]  S. Rosen,et al.  Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. , 1991, Blood.

[18]  G. Griffiths,et al.  Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. , 1991, Cancer research.

[19]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[20]  S. Raimondi,et al.  Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.

[21]  D. Bigner,et al.  Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. , 1991, Cancer research.

[22]  V. Raso,et al.  Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. , 1991, Cancer research.

[23]  D. Goldenberg,et al.  Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. , 1991, Cancer research.

[24]  S. Carroll,et al.  Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain. , 1991, Cancer research.

[25]  O. Leo,et al.  Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). , 1991, Journal of immunology.

[26]  R. Collins,et al.  Phase I immunotoxin trial in patients with B-cell lymphoma. , 1991, Cancer research.

[27]  F. Davey,et al.  Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia , 1991, Cancer.

[28]  J. Schlom,et al.  Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. , 1991, Cancer research.

[29]  J. Griffin,et al.  Prognostic value of lymphocyte surface markers in acute myeloid leukemia. , 1991, Blood.

[30]  K. Weinberg,et al.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. , 1991, The New England journal of medicine.

[31]  D. Scheinberg,et al.  A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Montserrat,et al.  Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia , 1990, British journal of haematology.

[33]  D. Scheinberg,et al.  A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Behm,et al.  Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy , 1990 .

[35]  F. Behm,et al.  Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. , 1988, Blood.

[36]  L. Smith,et al.  Lineage infidelity in acute leukemia. , 1983, Blood.